EDSA - Edesa Biotech, Inc. Summary, Stock Quote and News | Benzinga

Market Overview

4.320 -0.1 (-2.26%)

Data as of Dec 15, 2019

Prev. Close 4.42
Price Open 4.53
Volume 8,336
Day's Range 4.29 - 4.53
52 Wk Range 3.28 - 17.399965
50 Day Moving Avg. 5.2
PE Ratio 0
Shares Outstanding 7.50M
Market Cap 32.42M

Trade EDSA stock with recommended broker Ally Invest. Commissions as low as $3.95.

Analyst Rating View All Ratings

Edesa Biotech Reports Healthy Volunteer Data And Expands Phase 2b Dermatitis Study To Patients With Facial Lesions Benzinga NewsdeskTue, 03 Dec 2019 07:32:25 -0500
Edesa Biotech Enrolls its First Patient in Phase 2b Dermatitis Study Benzinga NewsdeskMon, 21 Oct 2019 06:35:37 -0500
42 Biggest Movers From Yesterday Lisa LevinWed, 09 Oct 2019 04:05:11 -0500
46 Biggest Movers From Yesterday Lisa LevinFri, 20 Sep 2019 03:45:11 -0500
32 Stocks Moving In Thursday's Mid-Day Session Lisa LevinThu, 19 Sep 2019 11:54:58 -0500
52 Biggest Movers From Yesterday Lisa LevinThu, 19 Sep 2019 04:18:04 -0500
80 Biggest Movers From Yesterday Lisa LevinWed, 11 Sep 2019 04:11:13 -0500
64 Biggest Movers From Friday Lisa LevinMon, 09 Sep 2019 04:43:53 -0500
46 Stocks Moving In Friday's Mid-Day Session Lisa LevinFri, 06 Sep 2019 11:09:16 -0500
A Look At Benzinga Pro's Most-Searched Tickers For September 6, 2019 Hal LindonFri, 06 Sep 2019 10:45:35 -0500
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Edesa Biotech Reports Financial Results for Short Period Fiscal Year ACCESSWIRE2 days ago
Edesa Biotech Reports Positive Healthy Volunteer Data and Expands Phase 2b Dermatitis Study to Patients with Facial Lesions ACCESSWIREDec 03, 2019
Edesa Biotech Announces Upcoming Conference Schedule ACCESSWIRENov 05, 2019
Edesa Biotech Enrolls First Patient in Phase 2b Dermatitis Study ACCESSWIREOct 21, 2019
Edesa Biotech Receives Approval to Initiate Clinical Study in Patients with Hemorrhoids ACCESSWIRESep 05, 2019
Edesa Biotech to Present at H. C. Wainwright Global Investment Conference ACCESSWIREAug 29, 2019
Edesa Biotech Reports Quarterly Financial Results ACCESSWIREAug 14, 2019
Edesa Biotech Completes Manufacturing for Upcoming Dermatitis Study ACCESSWIREJul 25, 2019
Edesa Biotech Receives Approval to Proceed with U.S. Clinical Study PRNewswireJun 20, 2019
Edesa Biotech Receives Approval to Proceed with U.S. Clinical Study PRNewswireJun 20, 2019
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Edesa Biotech reports 9M results Seeking Alpha2 days ago
Edesa Bio enrolls first patient in mid-stage dermatitis study Seeking AlphaOct 21, 2019
Microcaps mostly among midday movers Seeking AlphaSep 19, 2019
AIM ImmunoTech leads healthcare gainers; Zynerba Pharmaceuticals leads the losers Seeking AlphaSep 19, 2019
FDX, MDR, PTCT and ROAD among midday movers Seeking AlphaSep 18, 2019
AUTL, CRWD, DOCU and ENDP among midday movers Seeking AlphaSep 06, 2019
ADPT, CLDR, GIII, LVGO and MDP among midday movers Seeking AlphaSep 05, 2019
PANW, EQNR among premarket top gainers Seeking AlphaSep 05, 2019
Edesa on go with study of EB02 for internal hemorrhoids; shares up 27% premarket Seeking AlphaSep 05, 2019
Mixed shelf roundup Seeking AlphaAug 31, 2019
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Company Profile

Read More

Brokerage Center

Compare All Online Brokerages

Book A Demo

Learn How You Can Succeed In The Market With Benzinga Pro

Fastest Market News

Real-Time News Alerts

Customizable News Filters

Book A Demo